EGFR and head and neck squamous cell carcinoma: Cetuximab, a monoclonal antibody against EGFR, has been the only approved targeted therapy for HNSCC since 2016, and was proposed to replace cisplatin to de-intensify current treatment regime for HPV-positive HNSCC to decrease adverse side effects [6–8].